Compare Neurocrine Biosciences Inc (NBIX) vs GraniteShares 2x Long NVDA Daily ETF (NVDL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs GraniteShares 2x Long NVDA Daily ETF — how do they compare? Neurocrine Biosciences Inc trades at $143.97 (market cap $14.36B), while GraniteShares 2x Long NVDA Daily ETF trades at $36.85 (market cap $3.56B). The key difference: Neurocrine Biosciences Inc is far larger — about 4× GraniteShares 2x Long NVDA Daily ETF's market cap, and GraniteShares 2x Long NVDA Daily ETF is trading nearer its 52-week high, Neurocrine Biosciences Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and GraniteShares 2x Long NVDA Daily ETF for 15 Days on average.
| NBIX | NVDL | |
|---|---|---|
Market Cap | $14.36B | $3.56B |
Volume | 1,237,180 | 9,740,643 |
Sector | Health | Leveraged / Inverse |
52-Week High | $185.50 | $43.02 |
52-Week Low | $123.10 | $21.76 |
Typical Hold Time | 23 Days | 15 Days |
Enterprise Value | $14.37B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $142.84, down 0.44% today, with strong fundamental performance including three consecutive quarterly earnings beats and robust profitability metrics. The stock shows bearish technical signals with resistance at $142-145, while maintaining excellent analyst support with 86% buy ratings and a $204 consensus target. Recent developments include pipeline advancements in Prader-Willi syndrome and executive appointments.
NBIX presents a compelling growth story with 20.9% net margins and expanding rare-disease portfolio, though faces execution risks as it diversifies beyond Ingrezza. The 43% upside to consensus target suggests significant potential, but investors must monitor pricing pressures and pipeline execution amid elevated valuation multiples.
NVDL (GraniteShares 2x Long NVDA Daily ETF) trades at $36.86, down 6.85% in the last session. Technical indicators show a bullish overall signal with moving averages supporting upward momentum while oscillators remain neutral. Recent news highlights Nvidia's strong Q2 2027 earnings beat and ongoing AI theme strength, though the leveraged ETF has underperformed NVDA's direct returns over the past year.
The outlook remains tied to Nvidia's AI leadership and market performance, with technical support at $36 and resistance at $39. Key risks include leverage decay and NVDA's high valuation, while institutional interest in AI and positive analyst coverage provide potential upside catalysts for the leveraged ETF structure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About GraniteShares 2x Long NVDA Daily ETF
NVDL is a leveraged ETF that seeks daily investment results corresponding to 200% (2x) of the daily performance of NVIDIA Corporation (NVDA) stock. It is designed as a tactical trading tool for investors with a strong bullish (long) view on NVDA. Due to the effects of compounding and leverage, the ETF is intended to be held for a single day and is not suitable for long-term investment, as its performance over longer periods may significantly deviate from two times the performance of the NVDA stock.
Read more on NVDL →
